oncbrain — oncology meeting digest

DeLLphi-304 (Tarlatamab CNS Outcomes)

Mon, 01 Jun 2026 00:00:00 GMT

[Caveats dominate] CNS PFS HR 0.54 ITT and 0.40 in brain-met subgroup; CNS CR 15% vs 5% favoring tarlatamab over chemo in 2L SCLC. Eligible: Relapsed SCLC, ≥1 brain metastasis, post-platinum (2L)

ctDNA in Nonoperative Management (Rectal Cancer)

Mon, 01 Jun 2026 00:00:00 GMT

[Early signal] Local-regrowth sensitivity only 41%; a negative ctDNA can't exclude regrowth, so it can't replace endoscopy/MRI surveillance in watch-and-wait. Eligible: Stage I-III MSS rectal adenoca in nonoperative mgmt after cCR/nCR

ARACOG (AFT-47)

Sat, 30 May 2026 00:00:00 GMT

[Confirmatory] Worst-domain cognitive decline (MCCD) -15.8% (DAR) vs -36.1% (ENZ) at 24wk, p=0.009; darolutamide spared cognition vs enzalutamide. Eligible: Advanced prostate cancer (mHSPC, nmCRPC, mCRPC) on AR pathway inhibitor

A-DREAM

Sat, 30 May 2026 00:00:00 GMT

[Early signal] 41% treatment-free with eugonadal testosterone recovery at 18mo (1° EP met, one-sided p=0.0249) after interrupting ADT+ARPI in deep-responding mHSPC. Eligible: mHSPC, deep responders (PSA<0.2) after ≥18mo ADT + ≥12mo ARPI

NRG Clinico-Transcriptomic Risk Stratification (Abstract 5000)

Sat, 30 May 2026 00:00:00 GMT

[Caveats dominate] 22-gene genomic classifier reclassifies ~¼ of NCCN ≥HR pts, refining who gets abiraterone intensification atop definitive RT+ADT in localized high-risk prostate. Eligible: NCCN high-risk/very-high-risk localized prostate cancer

GU Precision Oncology Biomarkers Discussion (Lang)

Sat, 30 May 2026 00:00:00 GMT

Education session on genomic biomarkers in prostate cancer; Decipher vs clinical-risk discordant in 24% of high-risk pts, with pre-ARPI validation caveats.

ENZAMET + Decipher

Sat, 30 May 2026 00:00:00 GMT

[Caveats dominate] OS HR 0.75 for docetaxel triplet vs doublet in Decipher >0.85 (interaction p=0.04); docetaxel avoidable if Decipher ≤0.85 in mHSPC. Eligible: mHSPC on ADT+enzalutamide, Decipher classifier-tested

TALAPRO-3

Sat, 30 May 2026 00:00:00 GMT

[Practice-changing] 3-yr rPFS 77% vs 56% (HR 0.48, 0.36-0.65, p<0.001) adding talazoparib to enza+ADT in HRR-deficient metastatic prostate cancer. Eligible: HRR-deficient metastatic prostate cancer, first-line, enza+ADT backbone

RAD-IO

Sat, 30 May 2026 00:00:00 GMT

[Early signal] 12-mo DFS 80% (40/50, 95% CI 0.67-0.89), clearing the ≥75% GO bar for durvalumab added to 55Gy/20fr chemoRT in MIBC bladder preservation. Eligible: Muscle-invasive bladder cancer, cT2-T3, 13% node-positive, median age 69

MIBC Post-pCR Management Review (Guercio)

Sat, 30 May 2026 00:00:00 GMT

Post-pCR MIBC: sandwich IO regimens continue planned adjuvant regardless of response; cisplatin-chemo alone → surveillance; pCR strongly prognostic (SWOG 8710 85% 5-yr OS).

PREPEC

Sat, 30 May 2026 00:00:00 GMT

[Confirmatory] Pre-pectoral implant improved 24mo BREAST-Q chest well-being +4.8 pts (1.0-8.7, p=0.01) vs sub-pectoral, but more unplanned implant loss (21% vs 15%). Eligible: Implant reconstruction after skin/nipple-sparing mastectomy

ROADS

Sat, 30 May 2026 00:00:00 GMT

[Challenges SOC] Surg bed recurrence 1% (GammaTile brachy) vs 12% (post-op SRS) in resected brain mets >2cm; 2-yr OS 62% vs 36%. Eligible: Resected brain metastasis >2 cm

CHRYSALIS-2

Sat, 30 May 2026 00:00:00 GMT

[Early signal] mOS 41.0 mo (95% CI 27.7-NE) with 1L amivantamab + lazertinib in treatment-naïve atypical EGFR-mutant NSCLC; single-arm, n=49. Eligible: Treatment-naïve atypical EGFR-mutant advanced NSCLC

ESAONA

Sat, 30 May 2026 00:00:00 GMT

[Challenges SOC] Intracranial ORR 95.5% vs 79.6% (p=0.0004) and iPFS HR 0.46 favoring asandeutertinib over osimertinib in 1L EGFR-mut NSCLC with brain mets. Eligible: 1L EGFR-mutated NSCLC with brain metastases

OptiTROP-Lung05

Sat, 30 May 2026 00:00:00 GMT

[Challenges SOC] mPFS NR vs 5.7mo, HR 0.35, adding TROP2 ADC sac-TMT to pembro in 1L PD-L1+ NSCLC; OS immature (HR 0.55). Eligible: Untreated stage IIIB-IV NSCLC, PD-L1 TPS≥1%, EGFR/ALK wild-type

Neo-CRAG

Sat, 30 May 2026 00:00:00 GMT

[Challenges SOC] Adding neoadj chemoRT (45Gy/25fx) to perioperative XELOX improved DFS (HR 0.75, mDFS 52.7 vs 24.4mo) and OS (HR 0.78, 67.5 vs 37.6mo) in high-risk LAGC. Eligible: High-risk locally advanced gastric/EGJ adenoca, ≥cT3N2, D2 resection

Living Longer, Living Better: GU Oncology Review (Rini)

Sat, 30 May 2026 00:00:00 GMT

Discussant round-up on curing GU cancers without sacrificing QoL: bladder-preservation chemoRT ± durvalumab, EV-based sparing, ctDNA-guided adjuvant RCC selection.

SPIN Score — Celiac Plexus Radiosurgery

Sat, 30 May 2026 00:00:00 GMT

[Caveats dominate] Pain response 32%→89% across the 0-2 score; severe baseline pain and no prior neurotoxic chemo predict who responds to celiac SRS. Eligible: Pancreatic cancer with intractable retroperitoneal/celiac pain

Wait or Treat

Fri, 29 May 2026 00:00:00 GMT

[Confirmatory] Upfront cranial RT cut intracranial progression (sub-HR 0.35) but didn't improve OS; 2y OS 48% vs 60% favored delayed RT. Eligible: Metastatic EGFR/ALK+ NSCLC, asymptomatic brain mets, on TKI+chemo